Journal article
Mechanism–Based Improvement in the Therapeutic Selectivity of 5-FU Prodrug Alone and Under Conditions of Metabolic Modulation
Oncology, Vol.54(Suppl 1), pp.7-11
1997
DOI: 10.1159/000227738
PMID: 8978578
Abstract
To compare the antitumor activity of Tegafur (150 mg/kg/day) with continuous intravenous infusion of 5-fluorouracil (5-FU) (12.5 mg/kg/day) and with oral UFT® (60 mg/kg/day) with and without low- or high-dose leucovorin (50 or 200 mg/kg/day), rats with advanced colon cancer were treated with Tegafur or UFT® 3 times daily for 28 days and 5-FU by continuous intravenous infusion for 28 days. UFT® alone had a complete remission (CR) rate of 38%, whereas Tegafur and 5-FU produced no CRs. When high-dose leucovorin was added, the CR rate for UFT® increased to 75%; Tegafur plus high-dose leucovorin resulted in only a partial remission rate of 50%, with no CRs; low-dose leucovorin was not as effective as the high dose. Hence, UFT® clearly offers significant therapeutic advantages over Tegafur and protracted infusion of 5-FU. High-dose leucovorin is essential for significant modulation of drug action in this tumor.
Details
- Title: Subtitle
- Mechanism–Based Improvement in the Therapeutic Selectivity of 5-FU Prodrug Alone and Under Conditions of Metabolic Modulation
- Creators
- Youcef M Rustum - Roswell Park Cancer Institute
- Resource Type
- Journal article
- Publication Details
- Oncology, Vol.54(Suppl 1), pp.7-11
- DOI
- 10.1159/000227738
- PMID
- 8978578
- eISBN
- 3318018007; 9783318018004
- ISSN
- 0030-2414
- eISSN
- 1423-0232
- Number of pages
- 5
- Language
- English
- Date published
- 1997
- Academic Unit
- Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine
- Record Identifier
- 9984359919802771
Metrics
6 Record Views